Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults

BACKGROUND: A phase 1 trial of a clade B HIV vaccine in HIV-uninfected adults evaluated the safety and immunogenicity of a DNA prime co-expressing GM-CSF (Dg) followed by different numbers and intervals of modified vaccinia Ankara Boosts (M). Both vaccines produce virus-like particles presenting mem...

Descripción completa

Detalles Bibliográficos
Autores principales: Buchbinder, Susan P., Grunenberg, Nicole A., Sanchez, Brittany J., Seaton, Kelly E., Ferrari, Guido, Moody, M. Anthony, Frahm, Nicole, Montefiori, David C., Hay, Christine M., Goepfert, Paul A., Baden, Lindsey R., Robinson, Harriet L., Yu, Xuesong, Gilbert, Peter B., McElrath, M. Juliana, Huang, Yunda, Tomaras, Georgia D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519050/
https://www.ncbi.nlm.nih.gov/pubmed/28727817
http://dx.doi.org/10.1371/journal.pone.0179597

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519050/
https://www.ncbi.nlm.nih.gov/pubmed/28727817
http://dx.doi.org/10.1371/journal.pone.0179597

Ejemplares similares